%0 Journal Article
%T Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
%A Debora Fumagalli
%A Evandro de Azambuja
%A Martine Piccart
%A Matteo Lambertini
%A Noam Pond¨¦
%A Rafael Caparica
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2019
%R 10.1177/1758835919827714
%X Achieving a pathologic complete response after neoadjuvant treatment is associated with improved prognosis in breast cancer. The CREATE-X trial demonstrated a significant survival improvement with capecitabine in patients with residual invasive disease after neoadjuvant chemotherapy, and the KATHERINE trial showed a significant benefit of trastuzumab-emtansine (TDM1) in human epidermal growth factor receptor 2 (HER2)-positive patients who did not achieve a pathologic complete response after neoadjuvant treatment, creating interesting alternatives of post-neoadjuvant treatments for high-risk patients. New agents are arising as therapeutic options for metastatic breast cancer such as the cyclin-dependent kinase inhibitors and the immune-checkpoint inhibitors, but none has been incorporated into the post-neoadjuvant setting so far. Evolving techniques such as next-generation sequencing and gene expression profiles have improved our knowledge regarding the biology of residual disease, and also on the mechanisms involved in treatment resistance. The present manuscript reviews the current available strategies, the ongoing trials, the potential biomarker-guided approaches and the perspectives for the post-neoadjuvant treatment and the management of residual disease after neoadjuvant treatment in breast cancer
%K breast cancer
%K chemotherapy
%K pathologic complete response
%K post-neoadjuvant
%K residual disease
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393951/